



**Media Contact:**

Shelley Parnell  
Sr. Director, Marketing & Investor Relations  
[parnell@visiongate3d.com](mailto:parnell@visiongate3d.com) or 480.703.9268

## VisionGate's Alan Nelson to Present at the Piper Jaffray Healthcare Conference

**PHOENIX (November 16 2016)** – VisionGate<sup>®</sup>, Inc., a biotech company focused on the early detection and prevention of lung cancer, announced today that Founder & CEO Alan Nelson, PhD will present at the 28<sup>th</sup> Annual Piper Jaffray Healthcare Conference on November 29, 2016, at the Lotte New York Palace Hotel in New York. Dr. Nelson is scheduled to present at 8:30 a.m. EST (Location: Track Seven - Kennedy 2 - 4th floor). He will be joined by VisionGate's President and Chief Commercial Officer, Scarlett Spring.

The Piper Jaffray Healthcare Conference is an invitation-only event that convenes nearly 200 biotechnology, specialty pharmaceutical, drug discovery, medical technology, medical diagnostics and devices and healthcare services companies for interactive presentations and discussions.

"We are very pleased to be making our debut at one of the most prestigious conferences in the healthcare industry," VisionGate's Nelson said. "It's a tremendous opportunity to showcase the exciting path we're on to impact lung cancer through breakthrough diagnostic technology, called Cell-CT, and the non-invasive LuCED test for early detection, including the pre-cancer condition known as dysplasia. Those with dysplasia would be treated with the company's drug called Iloprost, shown to reverse dysplasia in Phase II trials to prevent lung cancer."

For more information about VisionGate, please visit [www.VisionGate3D.com](http://www.VisionGate3D.com).

###

### **About VisionGate<sup>®</sup>**

VisionGate, Inc. is led by Dr. Alan Nelson, physicist, bioengineer and entrepreneur who previously developed the world's first and only automated screening test to detect cervical cancer, marketed globally today as FocalPoint by Becton Dickinson. VisionGate's proprietary LuCED test is a non-invasive diagnostic test for early-stage lung cancer, demonstrating exquisite sensitivity and specificity in blinded clinical studies. This physician-ordered, take-home sputum test is processed on the world's first automated 3D cell imaging platform, the Cell-CT, named aptly because it is similar in principle to taking a CT scan of individual cells, but using visible light without harmful radiation. Moreover, with the new exclusive patent license from the University of Colorado for the drug called Iloprost, VisionGate will drive the therapeutic market for chemoprevention of lung cancer and, ultimately, the eradication of this killer. With 145 issued patents in 13 countries, VisionGate expects to play a leading role in the battle against the world's number one cancer killer.